Introduction
Essential thrombocythemia (ET) is an acquired myeloproliferative neoplasm (MPN) characterized by an expansion of the megakaryocytic lineage, leading to an isolated elevation of platelets. (1) ET is often asymptomatic, but can also be revealed by vascular occlusive events or hemorrhagic manifestations. (2) (3) (4) The recently identified acquired JAK2V617F mutation in the Janus kinase 2 (JAK2) rapidly became the first molecular marker of Philadelphia-negative chronic MPN, found in about 60% of ET patients. (5) The presence of this mutation, especially in a homozygous state, seems to increase the risk of thrombosis. (6) (7) (8) Transient ischemic attack (TIA) (9) , stroke or cerebral venous thrombosis may complicate ET. (10) (11) (12) However, in patients with ET, the majority of neurological symptoms are transient and subjective (blurry vision, headache, tinnitus, dizziness…). (13, 14) Such manifestations were frequently reported in ET (in 20% to 55% of patients) although these figures should be interpreted with caution, as obtained in retrospective studies only. (14, 15) The etiology of these neurological symptoms and risks factors for their development are not known. (1) One could suspect a role for microvascular occlusion since anti-aggregation is known to be efficient for treating these symptoms, but no magnetic resonance imagery (MRI) study has documented this hypothesis. (12) Finally, the impact of the JAK2V617F mutation on the frequency of neurological symptoms has not been assessed so far.
We describe here the neurological symptoms that occurred in a series of 37 consecutive ET patients. We aimed to prospectively identify clinical and biological characteristics associated with neurological symptoms, and to detect possible abnormalities of cerebral perfusion with MRI. We also assessed the response of neurological symptoms to therapy. All the patients with neurological symptoms were referred to the neurologist and had complete neurological examination. Neurological thrombotic symptoms were defined as stroke, TIA or cerebral venous thrombosis. Other neurological symptoms were also recorded:
headache, tinnitus and dizziness, visual disturbance and others. A complete blood count (CBC) was recorded in all patients at time of ET diagnosis, and at time of onset of the neurological symptoms. Patients with neurological symptoms were investigated with brain MRI, including perfusion time-to-peak (TTP) weighted images when possible. Cardiovascular exploration (trans-thoracic echocardiography and supra-aortic echosonography) was also performed in patients presenting with true thrombotic symptoms.
This study was approved by PV-Nord institutional review board, and patient informed consent was obtained in accordance with the Declaration of Helsinki.
Statistical analysis
Non-parametrical variables were presented as median (with range). Qualitative variables were presented as absolute and relative frequencies.
Comparisons between categorical variables were tested by χ 2 or Fisher's exact test.
Results and Discussion
From January 1 st , 2008 to June 30 th , 2009, 37 new patients with a diagnosis of ET were managed in Hôpital Avicenne . Among them, 13 were subsequently referred to the neurologist for evaluation of neurological symptoms. Two patients had a long history of migraine-like manifestations before ET diagnosis. As characteristics of the headaches were not modified after ET diagnosis, these patients were excluded from this study. Symptoms found in the 11 remaining patients are presented in the table 1.
 Description of neurological symptoms
A cerebral thrombotic event (first disease manifestation leading to ET diagnosis) was recorded in 4 of the 11 patients (Table 1) . One patient presented persistent headache during diagnostic work-up of portal vein thrombosis, leading to the subsequent discovery of a cerebral venous thrombosis (CVT) by MRI. Three other patients had transient symptoms,
lasting from a few seconds to fifteen minutes, diagnosed as TIA (9): aphasia, amaurosis fugax and left hemiparesis. Two of these three patients had associated cardiovascular risk factors.
Subjective symptoms were recorded in eight patients, chronic cephalalgia being the most frequent (Table 1) . Cephalalgia had no particular characteristics, and patients did not describe any "aura like" episode before headache. The second most frequent neurological manifestation was transitory dizziness. Episodes were very brief, lasting from a few seconds to a few minutes. Two patients described bilateral visual disturbances, and one patient reported transient brief loss of consciousness without evidence of a triggering factors. All the patients had normal neurological examination. In all the cases, semiology was atypical, and could not be attributed to well defined syndromes.
 Imaging and laboratory investigations in patients presenting with neurological symptoms
Brain MRI was performed in 9/11 patients at time of neurological symptoms, including perfusion analyses in 7/11 ( Table 1) . Of note, all patients were already treated with ASA for a few days but still had neurological symptoms at time of MRI. In all but 2 patients, MRI was normal. In one patient described above, a left transverse sinus thrombosis was discovered. In the second patient, MRI showed a small sequela of a cerebellar infarct. This patient was complaining of fluctuating dizziness one year before the MRI was done. This image was considered as unrelated to the clinical symptoms, because dizziness had been fluctuating over one year, and the infarct was small and located in the cerebellar hemisphere. In the three patients who had TIA, cardiac transthoracic echography and supra-aortic echography and ultrasonography were performed and ruled out a cardiovascular etiology.
 Evolution of neurological symptoms during therapy
Among the 11 patients with neurological symptoms, 3 (including 2 with fluctuating dizziness and 1 with chronic cephalalgia) were already receiving an anti-aggregating agent at time of neurological symptoms. In the 8 remaining patients, one was excluded from assessment of the impact of low-dose aspirin (ASA) on neurological symptoms because she was already on anticoagulant treatment and did not receive ASA. ASA (100 mg/day) was started in the 7 other patients. In 3 of those 7, neurological symptoms rapidly resolved with ASA only. In 2 patients, symptoms significantly improved, but transient episodes persisted. In the remaining patients, ASA treatment had no efficacy on the neurological symptoms, which subsequently resolved when platelet count was normalized after the addition of a cytoreductive treatment. In these last 4 patients, in whom ASA alone was not fully efficient, combination of 2 anti-aggregating agents (aspirin plus clopidogrel) was prescribed in 3 patients without further improvement in their neurological symptoms.
Altogether, with respect to neurological symptoms, ASA treatment could be evaluated in 10 patients, and induced complete response in 3/10, partial response in 2/10, and failed in 5/10 patients, respectively. Combination therapy with ASA and a cytoreductive agent induced a complete response in 2/2 patients.
 Predictive risk factors for neurological symptoms
In the total cohort of 37 patients, we compared those presenting neurological symptoms (11/37) with those without neurological symptoms (26/37). The characteristics of both groups are shown in table 2.
There was no significant difference between both groups with respect to age, gender, associated cardiovascular risk factors, hemoglobin, platelet and leukocyte counts at time of ET diagnosis. The JAK2V617F mutation was found in 9/11 (82%) patients with neurological symptoms versus 14/26 (54%) in patients without symptoms (p=0.11).
Overall, we found in this prospective unselected cohort that 30% of the patients A trend for higher prevalence of the JAK2V617F mutation was found in patients with neurological symptoms than in patients with no symptoms, but the difference did not reach significance, possibly due to the relatively limited number of patients. This is in line with the fact that this mutation is a potential risk factor for thrombosis in ET, (6) (7) (8) but no study focused specifically on neurological symptoms. In this study, no other risk factor for the development of neurological symptoms could be identified among demographic, clinical or biological data. In particular, a high platelets count was not associated with the occurrence of neurological symptoms, in agreement with studies assessing risk factors for vascular events in ET. (24) Of note, Kesler reported a significant predominance of females in patients with neurological symptoms,(17) but this observation was not confirmed in our series.
In conclusion, in this prospective study of 37 consecutive ET patients, the incidence of neurological symptoms was 30%. Brain MRI was always normal in patients with subjective symptoms suggesting that MRI is not useful in the baseline evaluation of ET patients with atypical neurological symptoms, after careful exclusion of focal neurological deficits.
Response to ASA was heterogenous, only 30% of patients experiencing resolution of their symptoms. Addition of cytoreductive therapy should be considered in such patients.
JAK2V617F mutation could be a risk factor for developing neurological symptoms in ET, an observation that needs to be confirmed in a larger cohort of patients.
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